Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation

NCT00630435

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Menopause
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
35-70 years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

MenopauseStudy Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
NCT00195546
  1. Leuven,
  2. Zadar,
  3. Zagreb,
  4. Olomuc,
  5. Ostrava,
  6. Prerov,
  7. Kuopio,
  8. Kuopio,
  9. Oulu,
  10. Evry,
  11. Paris,
  12. Paris,
  13. Debrecen,
  14. Tatabanya,
  15. Del. Cuauhtemoc,
  16. Lomas Virrteyes,
  17. Den Bosch,
  18. Hengelo,
  19. Nijmegen,
  20. Katowice,
  21. Poznan,
  22. Warszawa,
  23. Wroclaw,
  24. Bucuresti,
  25. Bucuresti,
  26. Bucuresti,
  27. Bucuresti,
  28. Bloemfontein,
  29. Centurion,
  30. Parow,
  31. Madrid,
  32. Linköping,
  33. Stockholm,
  34. Uppsala,
  35. Donetsk,
  36. Kyiv,
  37. Kyiv,
  38. Fowey,
  39. Leicester,
  40. London,
  41. Plymouth,
Female
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation
Official Title  ICMJE An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of 3 New Formulations of Premarin® /MPA 0.625 mg/2.5 mg Compared With Reference Formulation of Premarin®/MPA in Healthy Postmenopausal Women
Brief Summary The purpose of this trial is to determine the equivalence of 3 new formulations of a Premarin®/medroxyprogesterone acetate (MPA) combination tablet to the currently marketed dosage form (Prempro® [TM]). This study will be performed in healthy postmenopausal women. Each subject will participate in the study for approximately 14 weeks, including a screening evaluation within 3 weeks before the study, and four, 6-day, 5-night inpatient periods with at least a 21-day washout interval between each dose administration.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Condition  ICMJE Menopause
Intervention  ICMJE
  • Drug: Premarin®/MPA formulation A
  • Drug: Premarin®/MPA formulation B
  • Drug: Premarin®/MPA formulation C
  • Drug: Premarin®/MPA currently marketed product
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: Premarin®/MPA formulation A
  • Experimental: 2
    Intervention: Drug: Premarin®/MPA formulation B
  • Experimental: 3
    Intervention: Drug: Premarin®/MPA formulation C
  • Active Comparator: 4
    Intervention: Drug: Premarin®/MPA currently marketed product
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: March 6, 2008)
76
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2008
Actual Primary Completion Date June 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion

  1. Healthy postmenopausal women aged 35 to 70.
  2. Body mass index of 18 to 35 kg/m2, weight must be at least 50 kg.
  3. Nonsmoker or smoker of fewer than 10 cigarettes/day.

Exclusion

  1. History or presence of hypertension (>139 mm Hg systolic or >89 mm Hg diastolic). Can take up to 2 antihypertensive medications to keep blood pressure under control.
  2. History within 1 year of study day 1 of alcohol or drug abuse.
  3. Use of any investigational drug within 30 days before study day 1.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 35 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00630435
Other Study ID Numbers  ICMJE 0713E1-1137
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP